抗血管渗透性因子药物在糖尿病性视网膜病变治疗中的应用以及安全性分析  

Application and Safety Analysis of Anti-vascular Osmotic Factor Drugs in the Treatment of Diabetic Retinopathy

作　　者：黄建峰 HUANG Jian-feng(Dehua Hospital of Traditional Chinese Medicine,Quanzhou 362000,China)

机构地区：[1]德化县中医院,福建泉州362000

出　　处：《海峡药学》2024年第4期68-70,共3页Strait Pharmaceutical Journal

摘　　要：目的 探讨抗血管渗透性因子药物在糖尿病性视网膜病变治疗中的疗效与安全性。方法 回顾性收集2021年10月到2022年5月期间我院72例糖尿病性视网膜病患者的临床资料,根据不同的治疗方式分为两组,A组(抗血管渗透性因子药物治疗联合激光组)和B组(激光组),每组各36例,比较两组患者治疗前、治疗3个月后的各项临床指标、生活质量评分以及治疗后3个月内并发症发生率。结果 A组治疗后各项临床指标、生活质量评分以及并发症发生率均较B组显著更优(P<0.05)。结论 抗血管渗透性因子药物的使用,可以显著提升糖尿病性视网膜病变患者的临床诊治效果,安全性高,适合推广使用。OBJECTIVE To investigate the efficacy and safety of anti-vascular osmotic factor drugs in the treatment of diabetic retinopathy.METHODS Clinical data of 72 patients with diabetic retinopathy in our hospital from October 2021 to May 2022 were retrospectively collected and divided into two groups according to different treatment methods:Group A(anti-vascular permeability factor drug therapy combined with laser group) and group B(laser group),with 36 cases in each group.The clinical indicators,quality of life scores and the incidence of complications within 3 months after treatment were compared between the two groups.RESULTS The clinical indexes,quality of life score and complication rate of group A after treatment were significantly better than those of group B,P<0.05.CONCLUSION The use of anti-vascular osmotic factor drugs can significantly improve the clinical diagnosis and treatment effect of diabetic retinopathy patients,high safety,suitable for promotion.

关 键 词：糖尿病性视网膜病变 抗血管渗透性因子药物 治疗效果 安全性 

分 类 号：R969[医药卫生—药理学]